Oncology Corporate Profile
Kyowa Hakko Kirin is a research-based life sciences company with special strengths in biotechnology. They are opening up the path toward the development of new biologics, and developing new medicines to meet medical needs that are currently not being satisfied by existing pharmaceuticals.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|mogamulizumab||anti-CCR4 humanized antibody||Cutaneous T-cell Lymphoma (CTCL)||II|
|KW-0761||anti-CCR4 humanized antibody||Various cancer types||I|
|KHK2804||Anti-Tumor specific glyco protien humanizes antibody||Various cancer types|
View additional information on product candidates here »